Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2014

Open Access 01-12-2014 | Research

Arsenic trioxide induces oxidative stress, DNA damage, and mitochondrial pathway of apoptosis in human leukemia (HL-60) cells

Authors: Sanjay Kumar, Clement G Yedjou, Paul B Tchounwou

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2014

Login to get access

Abstract

Background

Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML), which accounts for approximately 10% of all acute myloid leukemia cases. It is a blood cancer that is formed by chromosomal mutation. Each year in the United States, APL affects about 1,500 patients of all age groups and causes approximately 1.2% of cancer deaths. Arsenic trioxide (ATO) has been used successfully for treatment of APL patients, and both induction and consolidated therapy have resulted in complete remission. Recently published studies from our laboratory have demonstrated that ATO pharmacology as an anti-leukemic drug is associated with cytotoxic and genotoxic effects in leukemia cells.

Methods

In the present study, we further investigated the detailed molecular mechanism of ATO-mediated intrinsic pathway of apoptosis; using HL-60 cells as a test model. Oxidative stress was assessed by spectrophotometric measurements of MDA and GSH levels while genotoxicity was determined by single cell gel electrophoresis (Comet assay). Apoptosis pathway was analyzed by Western blot analysis of Bax, Bcl2 and caspase 3 expression, as well as immunocytochemistry and confocal imaging of Bax and Cyt c translocation and mitochondrial membrane potential depolarization.

Results

ATO significantly (p < 0.05) induces oxidative stress, DNA damage, and caspase 3 activityin HL-60 cells in a dose-dependent manner. It also activated the intrinsic pathway of apoptosis by significantly modulating (p < 0.05) the expression and translocation of apoptotic molecules and decreasing the mitochondrial membrane potential in leukemia cells.

Conclusion

Taken together, our research demonstrated that ATO induces mitochondrial pathway of apoptosis in HL-60 cells. This apoptotic signaling is modulated via oxidative stress, DNA damage, and change in mitochondrial membrane potential, translocation and upregulation of apoptotic proteins leading programmed cell death.
Appendix
Available only for authorised users
Literature
1.
Powell BL: Arsenic trioxide in acute promyelocytic leukemia: potion not poison. Expert Rev Anticancer Ther. 2011, 11: 1317-1319. 10.1586/era.11.128.CrossRefPubMed
2.
Jemal A, Thomas A, Murray T, Thun M: Cancer statistics. CA Cancer J Clin. 2002, 52: 23-47. 10.3322/canjclin.52.1.23.CrossRefPubMed
3.
Yedjou C, Tchounwou P, Jenkins J, McMurray R: Basic mechanisms of arsenic trioxide (ATO)-induced apoptosis in human leukemia (HL-60) cells. J Hematol Oncol. 2010, 3: 28-35. 10.1186/1756-8722-3-28.PubMedCentralCrossRefPubMed
4.
Stone RM, Maguire M, Goldberg M: Complete remission in acute promyelocytic leukemia despite persistence of abnormal bone marrow promyelocytes during induction therapy: experience in 34 patients. Blood. 1988, 71: 690-696.PubMed
5.
Kantarjian HM, Keating MJ, Walters RS: Acute promyelocytic leukemia. M. D. Anderson Hospital experience. Am J Med. 1986, 80: 789-797. 10.1016/0002-9343(86)90617-0.CrossRefPubMed
6.
Gallagher RE: Retinoic acid resistance in acute promyelocytic leukemia. Leukemia. 2002, 16: 1940-1958. 10.1038/sj.leu.2402719.CrossRefPubMed
7.
Soignet SL, Frankel SR, Douer D: United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001, 19: 3852-3860.PubMed
8.
Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lübbert M, Hänel M, Schmitz N, et al: Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013, 369: 111-121. 10.1056/NEJMoa1300874.CrossRefPubMed
9.
Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell RP: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998, 339: 1341-1348. 10.1056/NEJM199811053391901.CrossRefPubMed
10.
Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, Rostami S, Jahani M, Hosseini R, Mossavi A, Baybordi E, Khodabadeh A, Iravani M, Bahar B, Mortazavi Y, Totonchi M, Aghdami N: Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol. 2006, 17: 131-134.CrossRefPubMed
11.
Ghavamzadeh A, Alimoghaddam K, Rostami S, Ghaffari SH, Jahani M, Iravani M, Mousavi SA, Bahar B, Jalili M: Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol. 2011, 29: 2753-2757. 10.1200/JCO.2010.32.2107.CrossRefPubMed
12.
Park WH, Seol JG, Kim ES, Hyun JM, Jung CW, Lee CC, Kim BK, Lee YY: Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res. 2000, 60: 3065-3071.PubMed
13.
Soriano C, Creus A, Marcos R: Arsenic trioxide mutational spectrum analysis in the mouselymphoma assay. Mutat Res. 2008, 646: 1-7. 10.1016/j.mrfmmm.2008.08.014.CrossRefPubMed
14.
Patlolla AK, Tchounwou PB: Cytogenetic evaluation of arsenic trioxide toxicity in Sprague–Dawley rats. Mutat Res. 2005, 587: 126-133. 10.1016/j.mrgentox.2005.08.007.CrossRefPubMed
15.
Stevens JJ, Graham B, Walker AM, Tchounwou PB, Rogers C: The effects of arsenic trioxideon DNA synthesis and genotoxicity in human colon cancer cells. Int J Environ Res Public Health. 2010, 7: 2018-2032. 10.3390/ijerph7052018.PubMedCentralCrossRefPubMed
16.
Jiang XH, Wong BC, Yuen ST, Jiang SH, Cho CH, Lai KC, Lin MC, Kung HF, Lam SK: Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3. Int J Cancer. 2001, 91: 173-179. 10.1002/1097-0215(200002)9999:9999<::AID-IJC1039>3.0.CO;2-D.CrossRefPubMed
17.
Tchounwou PB, Yedjou CG, Dorsey WC: Arsenic trioxide-induced transcriptional activation and expression of stress genes in human liver carcinoma cells (HepG2). Cell Mol Biol (Noisy-le-Grand). 2003, 49: 1071-1079.
18.
Alarifi S, Ali D, Alkahtani S, Siddiqui MA, Ali BA: Arsenic trioxide-mediated oxidative stress and genotoxicity in human hepatocellular carcinoma cells. Onco Targets Ther. 2013, 6: 75-84.PubMedCentralPubMed
19.
Wang ZG, Rivi R, Delva L, König A, Scheinberg DA, Gambacorti-Passerini C, Gabrilove JL, Warrell RP, Pandolfi PP: Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PMLand PML-RARa independent manner. Blood. 1998, 92: 1497-1504.PubMed
20.
Akao Y, Mizoguchi H, Kojima S, Naoe T, Ohishi N, Yagi K: Arsenic induces apoptosis in B-cell leukemic cell lines in vitro: activation of caspases and down-regulation of Bcl-2 protein. Br J Haematol. 1998, 102: 1055-1060. 10.1046/j.1365-2141.1998.00869.x.CrossRefPubMed
21.
Zhang W, Ohnishi K, Shigeno K, Fujisawa S, Naito K, Nakamura S, Takeshita K, Takeshita A, Ohno R: The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms. Leukemia. 1998, 12: 1383-1391. 10.1038/sj.leu.2401112.CrossRefPubMed
22.
Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, Jin XL, Tang W, Li XS, Xong SM, Shen ZX, Sun GL, Ma J, Zhang P, Zhang TD, Gazin C, Naoe T, Chen SJ, Wang ZY, Chen Z: In vitro studies on cellular and molecular mechanisms of arsenic trioxide As2O3 in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with down-regulation of Bcl-2 expression and modulation of PML-RARa/PML proteins. Blood. 1996, 88: 1052-1061.PubMed
23.
Cai X, Yu Y, Huang Y, Zhang L, Jia PM, Zhao Q, Chen Z, Tong JH, Dai W, Chen GQ: Arsenic trioxide-induced mitotic arrest and apoptosis in acute promyelocytic leukemia cells. Leukemia. 2003, 17: 1333-1337. 10.1038/sj.leu.2402983.CrossRefPubMed
24.
Collins SJ, Ruscetti FW, Gallagher RE, Gallo RC: Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds. Proc Natl Acad Sci U S A. 1978, 75: 2458-2462. 10.1073/pnas.75.5.2458.PubMedCentralCrossRefPubMed
25.
Kumar S, Guha M, Choubey V, Maity P, Srivastava SK, Bandyopadhyay U: Bilirubin inhibits Plasmodium falciparum growth through the generation of reactive oxygen species. Free Radic Biol Med. 2008, 44: 602-613. 10.1016/j.freeradbiomed.2007.10.057.CrossRefPubMed
26.
Singh NP, McCoy MT, Tice RR, Schneider EL: A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res. 1988, 175: 184-191. 10.1016/0014-4827(88)90265-0.CrossRefPubMed
27.
Yedjou CG, Tchounwou PB: In-vitro cytotoxic and genotoxic effects of arsenic trioxide on human leukemia (HL-60) cells using the MTT and alkaline single cell gel electrophoresis (Comet) assays. Mol Cell Biochem. 2007, 301: 123-130. 10.1007/s11010-006-9403-4.PubMedCentralCrossRefPubMed
28.
Velma V, Tchounwou PB: Oxidative stress and DNA damage induced by chromium in liver and kidney of goldfish, carassius auratus. Biomark Insights. 2013, 8: 43-51.PubMedCentralPubMed
29.
Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976, 72: 248-254. 10.1016/0003-2697(76)90527-3.CrossRefPubMed
30.
Singh NK, Kundumani-Sridharan V, Kumar S, Verma SK, Kotla S, Mukai H, Heckle MR, Rao GN: Protein kinase N1 is a novel substrate of NFATc1-mediated cyclin D1-CDK6 activity and modulates vascular smooth muscle cell division and migration leading to inward blood vessel wall remodeling. J Biol Chem. 2012, 287: 36291-36304. 10.1074/jbc.M112.361220.PubMedCentralCrossRefPubMed
31.
Wissing D, Mouritzen H, Jaattela M: TNF-induced mitochondrial changes and activation of apoptotic proteases are inhibited by A20. Free Radic Biol Med. 1998, 25: 57-65. 10.1016/S0891-5849(98)00043-4.CrossRefPubMed
32.
Cossarizza A, Baccarani-Contri M, Kalashnikova G, Franceschi C: A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the Jaggregate forming lipophilic cation 5,5_,6,6_-tetrachloro-1,1_,3,3_-tetraethylbenzimidazolcarbocyanine iodide (JC-1). Biochem Biophys Res Commun. 1993, 197: 40-45. 10.1006/bbrc.1993.2438.CrossRefPubMed
33.
Guha M, Kumar S, Choubey V, Maity P, Bandyopadhyay U: Apoptosis in liver during malaria: role of oxidative stress and implication of mitochondrial pathway. FASEB J. 2006, 20: 1224-1226. 10.1096/fj.05-5338fje.CrossRefPubMed
34.
Chattopadhyay S, Fensterl V, Zhang Y, Veleeparambil M, Yamashita M, Sen GC: Role of interferon regulatory factor 3-mediated apoptosis in the establishment and maintenance of persistent infection by Sendai virus. J Virol. 2013, 87: 16-24. 10.1128/JVI.01853-12.PubMedCentralCrossRefPubMed
35.
Uslu R, Sanli UA, Sezgin C, Karabulut B, Terzioglu E, Omay SB: Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin Cancer Res. 2000, 6: 4957-4964.PubMed
36.
Jang M, Kim Y, Won H, Lim S, KRJ , Dashdorj A, Min YH, Kim SY, Shokat KM, Ha J, Kim SS: Carbonyl reductase 1 offers a novel therapeutic target to enhance leukemia treatment by arsenic trioxide. Cancer Res. 2012, 72: 4214-4224. 10.1158/0008-5472.CAN-12-1110.CrossRefPubMed
37.
Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, Han ZG, Ni JH, Shi GY, Jia PM, Liu MM, He KL, Ma J, Zhang P, Zhang TD, Paul P, Naoe T, Kitamura K, Miller W, Waxman S, Wang ZY, de The H, Chen SJ, Chen Z: Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood. 1997, 89: 3345-3353.PubMed
38.
Ma DC, Sun YH, Chang KZ, Ma XF, Huang SL, Bai YH, Kang J, Liu YG, Chu JJ: Selective induction of apoptosis of NB4 cells from G2 + M phase by sodium arsenite at lower doses. Eur J Haematol. 1998, 61: 27-35.CrossRefPubMed
39.
Baysan A, Yel L, Gollapudi S, Su H, Gupta S: Arsenic trioxide induces apoptosis via the mitochondrial pathway by upregulating the expression of Bax and Bim in human B cells. Int J Oncol. 2007, 30: 313-318.PubMed
40.
Kang YH, Lee SJ: The role of p38 MAPK and JNK in arsenic trioxide-induced mitochondrial cell death in human cervical cancer cells. J Cell Physiol. 2008, 217: 23-33. 10.1002/jcp.21470.CrossRefPubMed
41.
Catalani S, Carbonaro V, Palma F, Arshakyan M, Galati R, Nuvoli B, Battistelli S, Canestrari F, Benedetti S: Metabolism modifications and apoptosis induction after Cellfood™ administration to leukemia cell lines. J Exp Clin Cancer Res. 2013, 32: 63-10.1186/1756-9966-32-63.PubMedCentralCrossRefPubMed
42.
Niero EL, Machado-Santelli GM: Cinnamic acid induces apoptotic cell death and cytoskeleton disruption in human melanoma cells. J Exp Clin Cancer Res. 2013, 32: 31-10.1186/1756-9966-32-31.PubMedCentralCrossRefPubMed
43.
Huang Y, Hu J, Zheng J, Li J, Wei T, Zheng Z, Chen Y: Down-regulation of the PI3K/Akt signaling pathway and induction of apoptosis in CA46 Burkitt lymphoma cells by baicalin. J Exp Clin Cancer Res. 2012, 31: 48-10.1186/1756-9966-31-48.PubMedCentralCrossRefPubMed
44.
Okui T, Fujiwara Y: Inhibition of human excision DNA repair by inorganic arsenic and the comutageniceffect in V79 Chinese hamster cells. Mutat Res. 1986, 172: 69-76. 10.1016/0165-1218(86)90108-4.CrossRefPubMed
45.
Kryeziu K, Jungwirth U, Hoda MA, Ferk F, Knasmüller S, Karnthaler-Benbakka C, Kowol CR, Berger W, Heffeter P: Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair. Mol Cancer Ther. 2013, 12: 1073-1084. 10.1158/1535-7163.MCT-13-0065.CrossRefPubMed
46.
Kessel M, Liu SX, Xu A, Santella R, Hei TK: Arsenic induces oxidative DNA damage in mammalian cells. Mol Cell Biochem. 2002, 234–235: 301-308.CrossRefPubMed
47.
Ninomiya M, Kajiguchi T, Yamamoto K, Kinoshita T, Emi N, Naoe T: Increased oxidative DNA products in patients with acutepromyelocyticleukemia during arsenic therapy. Haematologica. 2006, 91: 1571-1572.PubMed
48.
Jia P, Chen G, Huang X, Cai X, Yang J, Wang L, Zhou Y, Shen Y, Zhou L, Yu Y, Chen S, Zhang X, Wang Z: Arsenic trioxide induces multiple myeloma cell apoptosis via disruption of mitochondrial transmembrane potentials and activation of caspace-3. Chin Med J (Engl). 2001, 114: 19-24.
49.
Lu M, Levin J, Sulpice E, Sequeira-Le Grand A, Alemany M, Caen JP, Han ZC: Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leukemia cell lines. Exp Hematol. 1999, 27: 845-852. 10.1016/S0301-472X(99)00014-4.CrossRefPubMed
50.
Rousselot P, Labaume S, Marolleau JP, Larghero J, Noguera MK, Brouet JC, Fermand JP: Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cellsfrom myeloma patients. Cancer Res. 1999, 59: 1041-1048.PubMed
51.
Carvalho PS, Catian R, Moukha S, Matias WG, Creppy EE: Comparative study of domoic acid and okadaic acid induced -chromosomal abnormalities in the CACO-2 Cell Line. Int J Environ Res Public Health. 2006, 3: 4-10. 10.3390/ijerph2006030001.PubMedCentralCrossRefPubMed
Metadata
Title
Arsenic trioxide induces oxidative stress, DNA damage, and mitochondrial pathway of apoptosis in human leukemia (HL-60) cells
Authors
Sanjay Kumar
Clement G Yedjou
Paul B Tchounwou
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2014
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-33-42

Other articles of this Issue 1/2014

Journal of Experimental & Clinical Cancer Research 1/2014 Go to the issue

Research

CD45RA-Foxp3high but not CD45RA+Foxp3low suppressive T regulatory cells increased in the peripheral circulation of patients with head and neck squamous cell carcinoma and correlated with tumor progression

Research

TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities

Research

A four-long non-coding RNA signature in predicting breast cancer survival

Research

Transactivation of epidermal growth factor receptor through platelet-activating factor/receptor in ovarian cancer cells

Research

The expression profile of Dopamine D2 receptor, MGMT and VEGF in different histological subtypes of pituitary adenomas: a study of 197 cases and indications for the medical therapy

Research

Ultrasound features of medullary thyroid carcinoma correlate with cancer aggressiveness: a retrospective multicenter study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits